"This is an important reference for practicing medical oncologists, urologists, and researchers interested in the biology and therapy of this disease. ... This book details the most recent research into the molecular targets of RCC and applications for clinical drug development. ... It should be part of libraries for clinicians or basic scientists dealing with RCC. It certainly is an excellent reference for basic and translational scientists and clinicians in this field." (Jianqing Lin, Doody's Book Reviews, February, 2015)
Ch. 9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status
Linda Cerbone, M.D., Cora N. Sternberg, M.D., F.A.C.P.
Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity?
Hui Zhu, M.D., Ph.D., Brian I. Rini, M.D. F.A.C.P.,
Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC
Bernard Escudier, M.D., Laurence Albiges, M.D.
Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC
Daniel C. Cho, M.D., James W. Mier, M.D.
Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma
Egbert Oosterwijk, Ph.D., Otto C. Boerman, Ph.D., Jeannette C. Oosterwijk-Wakka, B.Sc. Wim J. Oyen, M.D., Ph.D., Peter F. A. Mulders, M.D., Ph.D.
Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma
Sarathi Kalra, M.D., Eric Jonasch, M.D.
Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma
Fabiola Cecchi, Ph.D., Young H. Lee, Ph.D., Benedetta Peruzzi, Ph.D., Jean-Baptiste Lattouf, M.D. Donald P. Bottaro, Ph.D.
Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance
James W. Mier, M.D., Rupal S. Bhatt, M.D., Ph.D., David J. Panka, Ph.D., Michael B. Atkins, M.D.
Ch. 17: Development of Combination Therapy with Targeted Agents
C. Lance Cowey, M.D., Thomas E. Hutson, D.O., Pharm.D., F.A.C.P.
Ch. 18: Side Effects of Targeted Thearpy
Luis Leon, M.D., Luis Miguel Anton Aparicio, M.D., Emilio Esteban Gonzalez, M.D., Martin Lazaro Quintela, Ph.D., Sergio Vazquez Estevez, M.D.
Ch. 19: The Role of Targeted Therapy in Special Populations
James M.G. Larkin, Ph.D., F.R.C.P., Martin E. Gore, Ph.D., F.R.C.P.
Ch. 20: Immunotherapy: the Current Role of Cytokines
Mayer Fishman, M.D., Ph.D.
Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC
David F. McDermott, M.D., Alexandra Bailey, M.D.
Ch. 22: Vaccines in RCC: Clinical and Biological Relevance
Devin B. Lowe, Ph.D., James H. Finke, Ph.D., Jorge A. Garcia,Walter J. Storkus, M.D.
Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics
Sumanta K. Pal, M.D., Robert A. Figlin, M.D.
Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma
Steven G Koopman, M.D., Ali-Reza Sharif-Afshar, M.D., Robert A Figlin, M.D., Hyung L Kim, M.D.
Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma
Nimira Alimohamed M.D., Toni K. Choueiri M.D., Daniel Y.C. Heng M.D.
Ch. 26: The Role of Advocacy in Renal Cell Carcinoma
William P. Bro, B.S.B., Paul Larson, M.S.
Ronald M Bukowski MD Emeritus Staff Physician Cleveland Clinic Taussig Cancer Center Professor Emeritus of Medicine CCF Lerner College of Medicine of CWRU
Robert Figlin MD Professor of Medicine and Biomedical Sciences Director, Division of Hematology Oncology Department of Medicine, Cedars-Sinai Medical Center Associate Director for Academic Programs Samuel Oschin Comprehensive Cancer Institute Professor Emeritus of Medicine and Urology David Geffen School of Medicine at UCLA
Robert Motzer MD Attending Physician Department of Medicine Memorial Sloan-Kettering Cancer Center Professor of Medicine Weil Medical College of Cornell University
The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors.
Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.